Connect with us

Insight

Tackling women’s mental health with music and tech

Published

on

By Tuned Global

Mental health problems affect both men and women, but not in equal measure. According to the Mental Health Foundation, one in five adults has a common mental health condition: about 24 per cent of women and 15 per cent of men.

The Mind Organisation also reveals women are more likely to have suicidal thoughts and to make suicide attempts than men. So how can music therapy help?

At a recent industry event, audiences attending a session on music in the medicine and research space gained insights into the therapeutic benefits of music, such as treating conditions including dementia, Parkinson’s disease, PTSD and ADHD. 

Three experts sat down to discuss this exciting and complex space and to explore how in trying to bring these treatments to patients or the broader market, the not-so-common intersection of medtech and music surfaces a number of challenges. 

How AI can strengthen music therapies

                             Felicity Baker

Music therapy itself is not new, and therapists have been delivering such interventions in one-on-one sessions and small groups for decades.

The exciting prospect highlighted during the session was that technology and AI can now enable this at scale and with evidence-based approach. 

If more people can gain access to music treatment through technology, there is the potential to decrease medication intake, reduce healthcare costs and improve outcomes.

However, scaling these therapies does introduce new considerations and challenges that traditional clinical settings have not had to face. 

Felicity Baker is a music therapist, professor at the University of Melbourne and Founder of Matchplus.ai, a sensor-based AI solution that detects early physiological markers of agitation and delivers personalised music interventions to improve the wellbeing of people living with dementia and other cognitive conditions.

With over three decades of experience in dementia care and music therapy, Baker is leading this project at prototype stage to reduce distress, medication reliance and create a more enabling environment for individuals with cognitive decline.

Having successfully secured USD $1.3m from Google.org (the philanthropic arm of Google LLC) to develop scalable technology, Baker has become one of just 15 recipients worldwide from more than 800 applications.

“We’re using wearables to actually develop algorithms that can predict when someone is going to start wandering or is going to get up and have a fall or hit another resident in the nursing home,” she said. 

“We’ve got it down to between five and 15 minutes, so a carer or family member can anticipate that something’s going to happen.”

Baker said using AI to help preempt when to use music was one thing, but then what order the music should come in, what kind of music and how to be sensitive to the specific symptoms of people with dementia created further challenges they continue to work on.

Simone Dalla Bella, co-director of the BRAMS laboratory at the University of Montreal is conducting research focused on rhythm interventions for patients with various disorders, including Parkinson’s disease.

                             Simone Dalla Bella

The interventions include rhythmic serious games such as Beat Workers, and mobile apps such as BeatMove, developed by the start-up BeatHealth that Dalla Bella co-founded.

For example, BeatMove can adjust music tempo to help Parkinson’s patients walk more effectively. 

“Imagine that you have music in the background that you chose, and the music is going a bit faster than you, so it motivates you to run a bit faster.

“But then if you’re tired and you slow down, the music will follow you gently as if you were running or walking with a theoretical partner,” he said. 

“A clinical trial is currently ongoing in France to test a large group of patients with Parkinson’s who basically take the app outside in a park, they use it, and we are seeing beneficial effects of that kind of intervention.”

Navigating music licensing challenges

The prospect of music-powered therapy is rather inspiring and life-affirming. Providing outcomes for patients with debilitating conditions in a non-invasive way is certainly a noble cause for academics and entrepreneurs alike to take up.

However, what many might not have considered is how these medical applications acquire and manage music rights. 

Virginie Chelles, VP and Global Head of Marketing and Communications for music licensing and technology company Tuned Global, described the complexity facing these innovators.

In working with medical technology clients, Chelles highlighted that while founders deeply understand the science and tech behind their products and projects, they often have no knowledge of music industry operations.

“When it comes to us, there is a whole new industry, being the music industry which has little or no connection with the medical industry, [which in itself also] has a lot of regulation,” she said.  

In the medical music space, Tuned Global currently works with MediMusic, a UK startup that uses AI to analyse brain responses and select music for anxiety and pain management.

Companies like MediMusic are obviously performing powerful and important work, but in cases where they are not up to speed on all of the requirements to correctly licence music, they are adding layers of risk to an already compliance-heavy environment. 

                           Virginie Chelles

“They’re dealing with the legal side of medicine in being able to have it delivered in NHS Hospitals in the UK, and going for trials and all that is involved.

“There is a lot of paperwork to do there,” Chelles said. “But then, if they play the wrong track, [a] track that was not licensed, the business is in trouble.”

“[They would be looking at lawsuits], and they wouldn’t be paying the rights to the right people. There are master rights, there’s publishing rights. [So they think], ‘How do I do that? How do I find the right tracks?’.” 

Often in these kinds of apps, an AI personalisation solution will drive the selection of tracks that resonate with certain patients, so another challenge for medtech clients in knowing the extent of what other tracks they will need access to.

Companies must also consider whether their licenses permit training medical algorithms on music assets. 

“Thousands of tracks are released every day, and [if you look at what’s being produced] with AI. It’s even more,” she said. 

“Many companies don’t need millions of tracks. If you work on dementia, just working on a back catalogue, like the catalog that makes sense for these people when they were in their 20s. 

“For us, it helped us to understand what you need to license the right catalog, rather than millions of tracks, because accessing millions of tracks is a lot of money in storage and in processing.” 

Understanding music licensing early in the innovation process

For medtech companies wanting to leverage music, Chelles was direct about the challenges and decisions they face when they first approach music licensing.

A lot of consideration needs to be made about how much music they need, what kind, whether they need commercial music or production music and more. 

When MediMusic first engaged Tuned Global, these considerations presented a big challenge.

“Because licensing music is not a science. It’s not predictable, but we can definitely help,” she said. 

Elaborating further, Chelles said that companies tended to be more successful when they addressed music licensing early in development rather than treating it as an afterthought.

“It’s going to take as much time to build the music and the licensing and compliance technology as building your medical device or app or science behind it,” 

“Talk to a music expert early on, it can be us, but it can also be entertainment lawyers or licensing specialists that are going to be able to help from the beginning … to just understand what it is about.

“We can also help them to build their business case to pitch to those labels, because this can be quite strategic depending on the label and their current objectives.

“Making big pitches without understanding them or the broader environment could cost a lot of time and money if they don’t sign you up right away.

“Being able to demonstrate and communicate value in this industry on the industry’s terms is really important for success, so if you can work with people that have these relationships and can engage with them it’s very helpful.” 

Working with an established music technology company can help medtech startups navigate label negotiations. Labels recognise that companies already working with licensing specialists have typically secured funding and understand the commercial requirements.

“[The labels are] like, okay, they are legit, because if Tuned Global can work with them, they already have the funding and they understand what they’re doing,” Chelles said. 

Securing licensing agreements is only the first step. Companies then need backend technology to access the actual tracks.

Tuned Global maintains 190 million tracks, with the catalog growing daily.

Companies must negotiate separately with both master rights holders (the record labels) and publishers who represent musicians and writers.

Commercialising research and innovation

Neither researcher came from a background that prepared them for music industry negotiations.

Despite publishing in The Lancet and Nature and securing major medical research grants, Baker found music licensing remained unfamiliar territory.

Dalla Bella received more than $USD 3.5m in European research funding but similarly had no training in navigating music rights.

Startup activity at universities is growing, but this has not always been the case.

Baker noted that while the institutions themselves were very supportive and really wanted to push research innovations into the market, there still exists some commercialisation stigmas among some researchers. 

“For some researchers, commercialising your research is kind of almost like a dirty word.

“To them it’s like you’re not being true to the science if you want to actually make a company and do something with this,” she said. 

Dalla Bella described how moving from pure research into commercial applications required stepping outside his comfort zone.

“Sometimes in science, we’re very closed, right?

“We do work just in science, in our niche, we are happy with what we do, but then you have to go beyond your comfort zone to start to work with engineers and start to work with a startup company,” he said.

“[I’ve seen for a lot of people] it took time to build this collaboration, this common language, and to be able to work together. After a certain amount of time, you discover the real potential of doing that.”

The future of tech powered music therapies

The medical music technology sector is an exciting and expanding space.

As more innovators enter the industry, the intersection between healthcare regulation and music licensing will likely require more standardised frameworks and understanding of the complexities so they aren’t bogged down or exposed to complications that could cut their journey to provide care short.

For now, companies navigating both industries must build relationships with experts in each domain.

The medical science may be groundbreaking, but without proper music licensing infrastructure, therapeutic applications cannot reach patients or compensate the artists whose work makes treatment possible.

About Tuned Global

Tuned Global is the leading data-driven cloud and software platform that empowers businesses to integrate commercial music into their apps or launch complete streaming experiences using advanced APIs, real-time analytics, licensing solutions, and customisable white-label apps.

Our turnkey solutions for music, audio, and video — coupled with a broad ecosystem of third-party music tech integrations — make us the most comprehensive platform for powering any digital music project. We streamline complexities in licensing, rights management, and content delivery, enabling rapid innovation and bringing new ideas to life.

Since 2011, we’ve supported 40+ companies in 70+ countries — across telecom, fitness, media, aviation, and more — to deliver innovative music experiences faster and more cost-effectively.

For more information, visit www.tunedglobal.com.

Insight

From Hologic to Ark Surgical: Why Joseph LaBruzzo is betting on the future of women’s surgical innovation

Published

on

After more than two decades leading organisations at some of the world’s most respected medical device companies, including Hologic, SenoRx Breast Care, and BTL Industries, Joseph B. LaBruzzo is embarking on a new chapter as President & CEO of U.S. Operations and Board Member at Ark Surgical.

We sat down with Joseph to discuss what drew him to Ark Surgical, why he believes women’s surgical innovation is entering a transformative era, and what it takes to bring meaningful technologies from concept to standard of care.

You have held leadership positions at some of the biggest names in MedTech. What attracted you to Ark Surgical?

Throughout my career, I’ve been fortunate to work with organisations that developed technologies capable of changing the standard of care.

What attracted me to Ark Surgical is the opportunity to help address a meaningful unmet need in gynecologic surgery with an innovation that has the potential to improve patient outcomes while preserving the benefits of minimally invasive surgery.

Opportunities like that don’t come along very often.

FemTech World recently highlighted that many women remain unaware of gynecologic cancers and that unexpected diagnoses continue to have a profound impact on patients and families.

How has your own experience shaped the way you think about innovation in women’s health?

Earlier in my career, I witnessed many women receive life-changing cancer diagnoses.

Those experiences stayed with me and reinforced my belief that if there’s an opportunity to reduce risk through better innovation, it’s one worth pursuing.

That’s one of the reasons I was drawn to Ark Surgical.

The vast majority of minimally invasive gynecologic procedures are performed for conditions believed to be benign. Unfortunately, in rare cases, pathology later reveals an unexpected malignancy.

LapBox was designed with a proprietary dual-wall tissue containment system to help facilitate contained specimen retrieval and minimise the risk of tissue spillage during laparoscopic procedures.

I believe innovations like this can help surgeons manage the unexpected while preserving the many benefits of minimally invasive surgery for women.

Women’s health has gained significant momentum in recent years, yet surgical innovation often receives less attention than diagnostics or therapeutics. Why do you think that is?

Women’s health has historically been underfunded and underserved across many areas of medicine, and surgery is no exception.

While we’ve seen tremendous advances in diagnostics and pharmaceuticals, there are still important opportunities to improve the surgical experience for both physicians and patients.

Innovation that enhances safety, efficiency, and outcomes has the potential to make a lasting impact.

What excites you most about LapBox?

LapBox addresses a very real challenge that gynecologic surgeons face during minimally invasive procedures.

It was thoughtfully designed to integrate seamlessly into the surgical workflow while providing an added layer of confidence when tissue retrieval is required.

I believe technologies that solve real clinical challenges in a practical way have the greatest potential to become part of the standard of care.

What do you see as the biggest unmet needs in minimally invasive gynecologic surgery today?

The future of surgery isn’t simply about making procedures less invasive. It’s about making them smarter and safer.

Surgeons need technologies that integrate seamlessly into their workflow while helping them navigate increasingly complex clinical situations.

Every advancement that helps reduce risk while preserving the benefits of minimally invasive surgery has the potential to improve outcomes for both physicians and patients.

That’s where I believe the greatest opportunities for innovation exist.

As you take on this new role, what are your priorities over the next 12 months?

Our focus over the next 12 months is to build a strong foundation for growth. That means expanding physician partnerships, driving early clinical adoption, growing our team, and ensuring that more surgeons have access to technologies like LapBox.

At the same time, we’re focused on building strategic relationships with investors, healthcare systems, and industry partners that support our long-term vision.

What advice would you give entrepreneurs building the next generation of women’s health companies?

Start with a real clinical problem and never lose sight of the patient.

Great technology alone isn’t enough. You also need strong clinical evidence, physician advocates, and a clear market strategy. The companies that succeed are the ones that bring all of those pieces together while remaining focused on improving patient care.

About Joseph B. LaBruzzo

As President & CEO of U.S. Operations and Board Member, Joseph LaBruzzo is leading Ark Surgical’s U.S. growth strategy, physician partnerships, strategic investment initiatives, and organisational expansion, supporting the company’s mission to advance safer minimally invasive gynecologic surgery through innovative technologies.

Continue Reading

Insight

Cancer cells secretly hijacking fertility protein to survive chemo, research finds

Published

on

Cancer cells may hijack a fertility protein to repair damaged DNA and survive chemotherapy, research suggests.

The findings could point to a way of making existing cancer treatments more effective.

SYCP1 is a protein normally involved in producing sperm and eggs.

Researchers at the University of Liverpool found that the protein, previously thought to work only in reproduction, can be reactivated in cancer cells, where it helps tumours survive and grow.

SYCP1 usually helps chromosomes pair during meiosis, the form of cell division that produces reproductive cells.

In cancer cells, however, the protein appears to take on another role. It enters the nucleus, the cell’s control centre, binds directly to DNA and regulates genes involved in cell division and DNA repair.

DNA repair is how cells fix damage to their genetic code. In cancer, this process can help tumour cells survive treatment.

The researchers found that removing SYCP1 made cancer cells much more sensitive to chemotherapy drugs that damage DNA.

The findings suggest cancers may use SYCP1 to repair damage caused by treatment and continue growing.

Dr Urszula McClurg, lecturer in biochemistry, cell and systems biology at the University of Liverpool, said: “Our findings show that cancer cells can hijack proteins that normally exist only in reproductive tissues and give them completely new jobs.

“Understanding these unexpected functions opens up exciting opportunities to develop new treatments that make existing cancer therapies more effective.”

The work challenges the long-held belief that proteins active only in fertility have no biological relevance outside the reproductive system.

Researchers say these specialised proteins could provide new treatment targets across many types of cancer.

The study also offers a new view of how cancers evolve by repurposing developmental and reproductive processes.

The findings highlight SYCP1 as a candidate for future precision cancer therapies, which are treatments based on the specific biology of a patient’s cancer.

Continue Reading

News

What “women’s healthmaxxing” means for patient trust and the femtech industry

Published

on

Women’s health has become one of the most searched and shared topics online, from cycle syncing and cortisol management to menopause hacks, supplements, hormone testing and clinician-creator content.

That surge in attention, sometimes dubbed “healthmaxxing,” is changing how women find, evaluate and act on health information, and it is starting to reshape the relationship between patients, clinicians and the companies building products for this market.

For providers, the shift means patients are arriving better informed but also more exposed to unverified claims, putting pressure on clinicians to engage with online narratives rather than dismiss them.

For femtech and pharma companies, it opens a route to reach and educate consumers at scale, but also raises the stakes on credibility: products and messaging that ride the trend without clinical grounding risk eroding the trust the industry has spent years building.

Investors are watching the same dynamic from a different angle.

Attention-driven demand can be a signal of where the next wave of femtech growth will come from, but distinguishing genuine clinical need from viral momentum is increasingly part of due diligence.

The net effect is a widening gap between companies that treat cultural attention as a distribution channel for credible, evidence-based care, and those that risk being swept up in trends with little clinical substance behind them.

How that gap plays out will shape patient trust, clinical relationships and commercial opportunity across the women’s health industry for years to come.

These themes will be explored in more depth in an upcoming webinar, “Women’s Healthmaxxing: The Opportunity & Risks of Cultural Attention for the Women’s Health Industry,” hosted by the Women’s Health Innovation Summit (WHIS), featuring Ellen Wilcox (Listen Ventures), Jessica Bell van der Wal (Frame Fertility), Dr. Tosin Sotubo-Ajayi (NHS, BBC and more) and Nora Lansen (Elektra Health).

Register free for the webinar on 23 July 2026 at https://events.virtualpro.com/womens-health-series-webinar-july-2026/registration

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.